caa a22 4500 445335556 CHVBK 20180317142753.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1245/s10434-011-1729-9 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1729-9 Lymphatic Vessel Invasion is a Significant Prognostic Indicator in Stage IA Lung Adenocarcinoma [Elektronische Daten] [Kazuhito Funai, Haruhiko Sugimura, Toyohiko Morita, Yasumasa Shundo, Kei Shimizu, Norihiko Shiiya] Background: A radical resection is considered to be the most effective treatment for resectable non-small cell lung cancer. However, even when resected in early stages (T1aN0, T1bN0) up to 20% of patients will experience recurrence. The aim of this retrospective study was to evaluate the prognostic influence of lymphatic vessel invasion (LVI) in stage IA adenocarcinoma patients. Methods: From January 1983 to June 2003, a total of 229 consecutive patients with pT1a or T1b N0 M0 lung adenocarcinoma who had undergone radical resection and lymph node dissection were retrospectively reviewed. Sections stained by the hematoxylin-eosin and the Elastica van Gieson method were examined for the presence of LVI. The overall survival was estimated using the Kaplan-Meier method, log-rank test, and the Cox proportional hazards analysis. Results: The median follow-up was 81months. A total of 143 patients (62%) were able to be diagnosed with regard to the presence of LVI, while information was not provided for 86 patients (38%), who were therefore excluded from the study. LVI was noted in 22 of the evaluable patients (15%) and was not seen in the other 121 patients (85%). The 5-year overall survival rate of the LVI-negative group and the LVI-positive group was 94.5 and 70.9%, respectively (P = .003). A multivariate analysis revealed LVI to be an independent predictive factor (hazard ratio: 0.202; P = .001). Conclusion: LVI is an independent poor prognostic factor in patients with pathologic stage IA adenocarcinoma. The T1a and T1b patients with LVI both might benefit from adjuvant chemotherapy. Society of Surgical Oncology, 2011 Funai Kazuhito First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan aut Sugimura Haruhiko First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan aut Morita Toyohiko First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan aut Shundo Yasumasa First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan aut Shimizu Kei First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan aut Shiiya Norihiko First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan aut Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2968-2972 1068-9265 18:10<2968 2011 18 10434 https://doi.org/10.1245/s10434-011-1729-9 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1729-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Funai Kazuhito First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan aut NATIONALLICENCE 700 1- Sugimura Haruhiko First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan aut NATIONALLICENCE 700 1- Morita Toyohiko First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan aut NATIONALLICENCE 700 1- Shundo Yasumasa First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan aut NATIONALLICENCE 700 1- Shimizu Kei First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan aut NATIONALLICENCE 700 1- Shiiya Norihiko First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2968-2972 1068-9265 18:10<2968 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer